Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology
Advances in Pharmacology · 2025 · 159-209
DOI: 10.1016/bs.apha.2024.10.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Pharmacology, 2025. Verfasst von Sumaiya Nahid und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, United States. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 4, Phosphodiesterase 4 Inhibitors, Nervous System Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 145 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, United States.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, United States; UNMC Center for Drug Design and Innovation, University of Nebraska Medical Center, Omaha, NE,…
Zitieren
APA
Nahid, S., Saeedi, S., & Hopkins, C. R. (2025). Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology. Advances in Pharmacology, 159-209. https://doi.org/10.1016/bs.apha.2024.10.005
Vancouver
Nahid S, Saeedi S, Hopkins CR. Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology. Advances in Pharmacology. 2025:159-209. doi:10.1016/bs.apha.2024.10.005
BibTeX
@article{Nahid2025,
author = {Nahid, Sumaiya and Saeedi, Saeedeh and Hopkins, Corey R},
title = {Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology},
journal = {Advances in Pharmacology},
year = {2025},
pages = {159--209},
doi = {10.1016/bs.apha.2024.10.005}
}
EUVIMED